Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants

By H. Daniell, S. Streatfield, K. Wycoff. Trends in Plant Science, 2001

796 citations recorded by the source corpus.

The use of plants for medicinal purposes dates back thousands of years but genetic engineering of plants to produce desired biopharmaceuticals is much more recent. As the demand for biopharmaceuticals is expected to increase, it would be wise to ensure that they will be available in significantly larger amounts, on a cost-effective basis. Currently, the cost of biopharmaceuticals limits their availability. Plant-derived biopharmaceuticals are cheap to produce and store, easy to scale up for mass production, and safer than those derived from animals. Here, we discuss recent developments in this field and possible environmental concerns.

Subfields: Biotechnology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/b41a48166c20d8edccf375076904fa60431826c1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biotechnology

1. H. Daniell
2. R. Twyman
3. J. Grevich
4. P. Christou
5. E. Stoger
6. Stefan Schillberg
7. R. Fischer

In Molecular Biology

1. H. Daniell
2. R. Twyman
3. J. Grevich
4. P. Christou
5. E. Stoger
6. Stefan Schillberg
7. R. Fischer
8. G. Bonnett

Citations in the corpus

• Transient Expression of (2011, background): “These include, production of transplastomic plants in which the chloroplast genome rather than the nuclear genome is transformed (Daniell et al 2001) and transient gene expression (Fischer et al 1999).”
• Practical considerations for pharmaceutical antibody production in different crop systems (2002, background): “Plants are cost-effective and have a number of further advantages, for example in terms of safety and ease of scale-up (Daniell et al. 2001; Fischer and Emans 2000).”
• The biosafety of molecular farming in plants (2003, background): “Currently, pharmaceutical proteins are the major focus of this emerging technology (Fischer and Emans, 2000; Daniell et al., 2001b; Fischer et al., 2003) but plants can also be used to produce food and feed additives, biopolymers, industrial enzymes and research-grade technical proteins such as…”
• Sugarcane biotechnology: The challenges and opportunities (2005, background): “incorporating polygenic traits, hyperexpression of transgenes, containment of transgenes within the transgenic plants (Daniell, 1999; Daniell et al., 2001; Maliga, 2004) together with the”
• Chloroplast expression of His-tagged GUS-fusions: a general strategy to overproduce and purify foreign proteins using transplastomic plants as bioreactors (2004, background): “Although, chloroplasts have the ability to form disulfide bridges and fold foreign proteins in a biologically active form (Daniell et al. 2001; Staub et al. 2000), the recombinant human IFN-g expressed in this study is devoid of any cysteine residues, similar to the naturally occurring mature human…”
• An aerobiological framework for assessing cross-pollination in maize (2003, background): “More recently, maize has been engineered to produce proteins of pharmaceutical or industrial importance (Daniell et al., 2001; Giddings, 2001).”
• Chloroplast Genetic Engineering: Recent Advances and Future Perspectives (2005, background): “Because the technology for harvesting and processing plants and plant products has already been developed, the transition of plastid engineering in plants to large-scale production should not incur large setup costs (Daniell, Streatfield, and Wycoff, 2001).”
• Plant tissue culture: Current status, opportunities and challenges (2010, background): “The proteins of pharmaceutical interest may be expressed in a stable way in transgenic plants or through the transitory expression in tissues infected with virus, transfected with the coding genes for the proteins of interest (Daniell et al., 2001).”
• Plant-based production of biopharmaceuticals. (2004, background): “Potato was the first major system to be used for vaccine production, and transgenic potato tubers have been administered to humans in at least three clinical trials to date [18].”